Development of HPLC Methods for Individual Determination of 20 Active Pharmaceutical Ingredients for Ussing-Chamber Studies

Basit Öğe Kaydı
dc.authoridKAYNAK, Mustafa Sinan/0000-0003-2917-2407
dc.authoridAtes, Muge/0000-0001-9533-5791
dc.authorwosidAteş, Müge/ABI-1317-2020
dc.authorwosidAteş, Müge/IZE-1782-2023
dc.authorwosidKAYNAK, Mustafa Sinan/D-9453-2019
dc.contributor.authorKaynak, Mustafa Sinan
dc.contributor.authorAkgeyik, Emrah
dc.contributor.authorAtes, Muge
dc.contributor.authorCelebier, Mustafa
dc.contributor.authorSahin, Selma
dc.date.accessioned2024-08-04T20:42:57Z
dc.date.available2024-08-04T20:42:57Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: The aim of this study was to develop HPLC methods for individual determination of 20 active pharmaceutical ingredients (amoxicillin sodium, antipyrine, atenolol, caffeine, carbamazepine, cimetidine, enalapril, furosemide, hydrochlorothiazide, ibuprofen, ketoprofen, metoprolol tartrate, methyldopa, naproxen sodium, pindolol, piroxicam, propranolol HCl, ranitidine, theophylline, and verapamil HCl) to be used for determination of their intestinal permeabilities across Ussing-Chamber. Method: Two different stationary phases (Waters X-Bridge C18-150 x 4.6 mm, 5 mu m; and ACE 5 C18- 150 x 4.6 mm, 5 mu m) were used for the separation of the compounds. Three different aqueous phases (20 mM phosphate buffers pH 3.0, pH 6.0 and water) and two different organic phases (methanol and acetonitrile) were used to prepare the mobile phases. Total analysis time was shorter than 7 minutes for all applications. Result: The developed methods were validated according to the ICII guideline and found to be linear, sensitive, selective, precise and accurate. The developed methods could be applied for analyses of these compounds not only for Ussing-Chamber studies but also for other permeability studies.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [SBAG-113S203]en_US
dc.description.sponsorshipThis study was supported by Grant SBAG-113S203 from The Scientific and Technological Research Council of Turkey (TUBITAK).en_US
dc.identifier.doi10.2174/1573412912666161018145031
dc.identifier.endpage153en_US
dc.identifier.issn1573-4129
dc.identifier.issn1875-676X
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85012097891en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage145en_US
dc.identifier.urihttps://doi.org/10.2174/1573412912666161018145031
dc.identifier.urihttps://hdl.handle.net/11616/97690
dc.identifier.volume13en_US
dc.identifier.wosWOS:000393442100008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Pharmaceutical Analysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHPLCen_US
dc.subjectussing-chamberen_US
dc.subjectkrebs bufferen_US
dc.subjectactive pharmaceutical ingredienten_US
dc.subjectmethod developmenten_US
dc.titleDevelopment of HPLC Methods for Individual Determination of 20 Active Pharmaceutical Ingredients for Ussing-Chamber Studiesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu